Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CDKN2A H142R |
| Therapy | Palbociclib |
| Indication/Tumor Type | B-cell acute lymphoblastic leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CDKN2A H142R | B-cell acute lymphoblastic leukemia | sensitive | Palbociclib | Preclinical - Cell culture | Actionable | In a preclinical study, Ibrance (palbociclib) treatment inhibited viability of a B-cell acute lymphoblastic leukemia cell line expressing CDKN2A H142R in culture (PMID: 34369425). | 34369425 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34369425) | The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia. | Full reference... |